問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李正達

Recruiting

List

11Cases

2017-07-01 - 2022-12-20

Phase III

Completed
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  • Condition/Disease

    Treatment-resistant Depression

  • Test Drug

    ESKETAMINE

Participate Sites
7Sites

Recruiting4Sites

Terminated3Sites

劉嘉逸
Linkou Chang Gung Medical Foundation

Division of Psychiatry

李信謙
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

2020-01-13 - 2022-06-07

Phase III

Completed
A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor

  • Condition/Disease

    Major Depressive Disorder

  • Test Drug

    ESKETAMINE

Participate Sites
10Sites

Recruiting10Sites

2021-04-26 - 2024-07-22

Phase III

Completed
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended-Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment-Resistant Major Depressive Disorder

  • Condition/Disease

    Major Depressive Disorder

  • Test Drug

    ESKETAMINE

Participate Sites
4Sites

Recruiting1Sites

Terminated2Sites

2022-07-01 - 2024-09-20

Phase III

Completed
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, with an Additional 18-Week Blinded Extension Period

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
16Sites

Not yet recruiting3Sites

Recruiting11Sites

Terminated2Sites

2022-08-01 - 2028-07-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-04-01 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-07-01 - 2030-05-31

Phase III

Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

  • Condition/Disease

    Depressive Disorder (MDD)

  • Test Drug

    tablet

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2024-04-09

Phase II

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II

  • Condition/Disease

    Attention-Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    PDC-1421 Capsule

Participate Sites
5Sites

Recruiting5Sites

2021-08-01 - 2026-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-01-01 - 2025-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB